Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Go back to Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
(NASDAQ: CRNX) Delayed: 83.65 -0.07 (0.08%)
Previous Close $83.72    52 Week High
Open $83.78    52 Week Low
Day High $83.79    P/E N/A 
Day Low $83.64    EPS
Volume 4,268,877